Longeveron (LGVN) vs Medicus Pharma (MDCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Longeveron is the larger company by market cap ($7.7 million vs $138,967), about 55.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LGVN | MDCX |
|---|---|---|
| Share price | $2.40 | $0.0927 |
| Market cap | $7.65M | $138.97K |
| 1-day change | +1.27% | -9.03% |
| YTD return | — | -93.34% |
| 1-year return | — | -95.86% |
| EPS (TTM) | $-9.90 | $-119.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.30 | $139.00 |
| 52-week low | $2.30 | $0.084 |
| Distance from 52-week high | -80.49% | -99.93% |
| Analyst consensus | none | none |
| Avg. price target upside | +2452.08% | +4754.37% |
| Average volume | 92.38K | 92.96K |
| Shares outstanding | 3.04M | 1.50M |
| Employees | 38 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Longeveron is about 55.1 times larger than Medicus Pharma by market value ($7.65M vs $138.97K).
About Longeveron
LGVN stock →Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
LGVN vs MDCX FAQ
Which is bigger, Longeveron or Medicus Pharma?
Longeveron (LGVN) is larger, with a market capitalization of $7.65M compared with $138.97K for Medicus Pharma (MDCX).
Are Longeveron and Medicus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.